Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lung Transplantation Using Hepatitis C Positive Donors to Hepatitis C Negative Recipients
NCT03112044Phase 1Active, not recruiting
- Sponsor
- University Health Network
- Start
- Sep 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sofosbuvir + velpatasvir in hepatitis C (HCV), sponsored by University Health Network. Primary endpoint: Safety of transplantation from HCV positive donors to HCV negative recipients at 6 months. Started Sep 2017; status: active, not recruiting.
02
Drugs
sofosbuvir + velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03112044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03112044.